Log in to save to my catalogue

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8436591

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a randomized trial involving patients with previously untreated advanced renal-cell carcinoma, nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free and overall survival and the likelihood of response. A total of 19.7% of the patients in the combination group discontinued one or both of the trial dr...

Alternative Titles

Full title

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8436591

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8436591

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2026982

How to access this item